爱博医疗(688050) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥357,723,444.32, representing a decrease of 8.17% compared to the same period last year[3] - The total profit for the period was ¥80,847,202.96, down 35.46% year-on-year[3] - Net profit attributable to shareholders was ¥76,848,645.53, a decline of 29.85% compared to the previous year[3] - Basic earnings per share for the period were ¥0.40, reflecting a decrease of 31.03% year-on-year[3] - Total operating revenue for the first three quarters of 2025 reached ¥1,144,414,504.11, an increase of 6.4% compared to ¥1,075,267,105.77 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was ¥278,623,253.61, a decrease of 8.4% from ¥304,046,515.08 in the previous year[19] - Earnings per share (EPS) for the first three quarters of 2025 was ¥1.51, down from ¥1.68 in the same period of 2024[20] Assets and Liabilities - Total assets at the end of the period were ¥3,902,983,843.01, an increase of 11.61% from the end of the previous year[5] - Total assets increased to ¥3,902,983,843.01 from ¥3,496,968,135.88, representing a growth of 11.6%[16] - Total liabilities rose to ¥894,960,084.85, compared to ¥862,711,621.16, indicating an increase of 3.4%[16] - The company's goodwill increased to ¥190,861,311.37 from ¥139,107,544.38, marking a rise of 37.0%[15] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥230,096,531.01, an increase of 6.01%[3] - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $1.15 billion, an increase of 11.5% compared to $1.03 billion in the same period of 2024[25] - Net cash flow from operating activities amounted to $230.1 million, up from $217.1 million year-over-year, reflecting a growth of 6.9%[25] - Cash inflow from investment activities significantly increased to $1.00 billion, compared to $215.3 million in the first three quarters of 2024, marking a substantial rise of 365.5%[25] - The net cash flow from investment activities turned positive at $38.3 million, a recovery from a negative $597.1 million in the previous year[25] - Total cash and cash equivalents at the end of the period stood at $680.1 million, a significant increase from $266.2 million at the end of Q3 2024[26] - Cash inflow from financing activities decreased to $322.0 million from $492.0 million in the same period last year, reflecting a decline of 34.6%[25] - The net cash flow from financing activities was $49.1 million, down from $114.5 million in the previous year, indicating a decrease of 57.1%[25] - The company reported a net increase in cash and cash equivalents of $316.2 million, contrasting with a decrease of $265.6 million in the same period last year[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,214[11] - The largest shareholder, Jie Jiangbing, holds 24,490,410 shares, representing 12.66% of total shares[11] - The company has a total of 10 major shareholders, with the top two holding a combined 18.31% of shares[12] - The company reported no significant changes in the participation of major shareholders in margin trading and securities lending[12] Research and Development - Research and development expenses totaled ¥36,985,646.67, accounting for 10.34% of revenue, an increase of 0.09 percentage points[5] - Research and development expenses for the first three quarters were ¥70,221,069.34, a decrease of 9.2% from ¥77,654,725.68 in the previous year[19] Operational Insights - The decline in total profit was primarily due to decreased revenue from artificial lenses and contact lenses, influenced by national procurement policies and market competition[9] - The company has not disclosed any new product developments or market expansion strategies in the current reporting period[13] - There are no significant reminders or additional important information regarding the company's operational situation during the reporting period[13] - The company adjusted its financial statements due to a change in accounting standards, resulting in an increase in operating costs by ¥6,489,041.81[21] Other Financial Metrics - Total operating costs amounted to ¥830,567,968.09, up from ¥720,300,574.45, reflecting a year-over-year increase of 15.3%[18] - The return on equity was 2.74%, a decrease of 3.12 percentage points compared to the previous year[5] - The company reported non-recurring gains of ¥1,524,008.91 for the period[7] - Non-current assets decreased from ¥1,834,000,000 to ¥1,800,000,000, a decline of 1.84%[14] - Total current assets increased to ¥1,587,115,954.59 from ¥1,180,629,881.84, reflecting a growth of 34.38%[14] - Accounts receivable rose to ¥498,459,333.41 from ¥353,147,013.28, an increase of 41.16%[14] - The company received $991.2 million from investment recoveries, a significant increase from $214.9 million in the previous year, representing a growth of 361.5%[25]